Important Tips About the Benicar Lawsuits That Every Patient Should Know

Comments (0)

Since 2002, the drug Benicar has been approved by the U.S. Food and Drug Administration (FDA) to treat high blood pressure. Unfortunately, studies later linked the use of this drug to the development of sprue-like enteropathy. Sprue-like enteropathy is a gastrointestinal condition with potentially severe symptoms that may include diarrhea, dehydration, and weight loss. As a result, several lawsuits have now been filed against the drug’s maker.

7 Tips About the Benicar Lawsuits

What is the latest status of the lawsuits involving Benicar? The following is an overview:

  • In December 2014, a motion was filed with the U.S. Judicial Panel on Multidistrict Litigation seeking to centralize cases filed throughout the federal court system.
  • In March 2015, a transfer order was issued that centralizes all of the Benicar lawsuits.
  • Going forward, discovery proceedings will be coordinated into issues that are common to all claims.
  • There are currently approximately 45 federal Benicar lawsuits that are part of the multidistrict litigation.
  • Legal experts expect the number of these lawsuits to multiply quickly to hundreds or even thousands.
  • One reason for this is that adverse symptoms stemming from the use of the drug may not appear for months or even years.
  • Another reason is that the drug was used for approximately 11 years before the U.S. Food and Drug Administration first required the drug’s maker to update the warnings on the medication to warn against the potential for developing symptoms of sprue-like enteropathy.

If you were injured after using Benicar, it is important to not only familiarize yourself with the pending lawsuits, but also to consult with an attorney of your own. To learn more, we encourage you to reach out today at 855-947-0707.


Be the first to comment!

Post a Comment

To reply to this message, enter your reply in the box labeled "Message", hit "Post Message."


Email:* (will not be published)


Notify me of follow-up comments via email.